LYNPARZA 50MG

Description

Lynparza is feasible as oral tablets marketed and was started indicated as a maintenance treatment or monotherapy for the therapy of adult patients with relapsed epithelial ovarian, fallopian tube or primary peritoneal cancer

Lynparza is a prescription drug which used under the supervision of medical practioners

Indication

Lynparza is used for the treatment in patients with advanced ovarian cancer

Lynparza is used for the treatment in patients with HER2 – negative metastatic breast cancer.

Mechanism of action

PARP is small for Poly (ADP-ribose) polymerase. It is a protein whichproduced damaged cells to repair themselves. Olaparib blocks PARP working.

Some cancer cells commit on PARP to keep their DNA healthy. This contains cancer cells with a convert in the BRCA gene. So, when Olaparib blocks PARP from repairing DNA injury, the cancer cells die.

This kind of drug is called a cancer growth blocker.

ADME Properties

Absorption: Maximum plasma concentration 1 to 3 hours

Distribution: volume of distribution 167 +/-196 L, plasma protein binding is 82%

Metabolism: Primarily metabolised by CYP3A4

Elimination: Excreted through the urine 44% and 42% through the feces.

Half – life of Lynparza 11.9 hours

Dosage and administration

Ovarian cancer

Maintenance treatment of recurrent ovarian cancer

The tablet recommended dose is 300mg (two 150mg – mg tablets) PO BID

Continue treatment until disease progression or unacceptable toxicity

Monotherapy for advanced BRCA – mutated ovarian cancer

The tablet recommended dose is 300mg (two 150mg – mg tablets) PO BID

The capsules recommended dose is 400mg (eight 50mg- mg capsules) PO BID

Continue treatment until disease progression or unacceptable toxicity.

Maintenance treatment for advanced BRCA-mutated ovarian cancer

The tablet recommended dose is 300mg (two 150mg – mg tablets) PO BID

Follow the treatment until disease progression, undesirable toxicity or completion of 2 years of treatment

Finishing of 2 years of treatment

• Patients with full response (no radiologic evidence): discontinue treatment
• Patients with indication of disease and may asset from continuous treatment: cure beyond 2 years.

 Side effects

Common side effects for patients taking Olaparib

• Musculoskeletal pain
• Diarrhea
• Decreased platelet count
• Decreased Haemoglobin
• Nausea
• Decreased white blood cell count
• Abdominal pain
• Vomiting
• Upper respiratory tract infection
• Anemia
• Decreased neutrophils
• Fatigue (including weakness)
• Increased serum creatinine

Less common side effects of patients administrating Olaparib

• Vertigo
• Constipation
• Urinary tract infection
• Heartburn
• Decreased appetite
• Shortness of breath
• Myalgia
• Headache
• Skin rash
• Back pain
• Taste changes
• Cough
• Swelling

Drug interaction

When Lynparza co administrationwith myelosuppressive anticancer agents contains DNA damaging agents, indicate a potentiation and prolongation of myelosuppressive toxicity.

Interaction of strong CYP3A inhibitors (itraconazole, telithromycin, clarithromycin,) will increase Olaparib plasma concentration.

Co administration of strong CYP3A inducers (itraconazole, telithromycin, clarithromycin,) will decrease Olaparib plasma concentration.

Contraindication

None

Precautions

Haematological toxicity will be resulted in patientsincluding diagnoses or findings of commonly mild or moderate anaemia, neutropenia, thrombocytopenia and lymphopenia.

When Lynparza monotherapy administrated to patient the incidence of myelodysplastic syndrome will occur.

On basis of mechanism of action (PARP inhibition), Lynparza could cause risk to fetal when administered to a pregnant woman.

Lynparza combination with strong or moderate CYP3A inhibitors is not recommended.

Pregnancy

Based on Lynparza mechanism of action, the drug causes risk to the fetal may occur when administrated to a pregnant woman.

Lactation

No data available on the presence of Lynparza in human milk, hence avoid breast feeding during the treatment.

Storage

Store at 20⁰C to 25⁰C

Missed dose

If dose is failed, then have the dose as soon as possible before next dose timing reaches or skip the missed dose and continue the regular schedule.

Must Consult doctors regarding missed dose.